- •The majority of endometrial cancer recurrences are symptomatic, and pain is the most common symptom.
- •Vaginal bleeding was reported in less than a quarter of symptomatic presentations.
- •More than a third of recurrences were diagnosed outside of the oncologic care team and frequently in the emergency room.
- •Seventeen percent of patients were unable to receive treatment for recurrent disease.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer statistics, 2022.CA Cancer J. Clin. 2022; 72: 7-33https://doi.org/10.3322/caac.21708
- Cancer of the cervix uteri.in: LAG Ries Young J.L. Keel G.E. Eisner M.P. Lin Y.D. Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics. SEER Survival Monograph. National Cancer Institute, Bethesda, MD2007 (NIH publication no. 07-6215)
- The changing landscape of gynecologic cancer mortality in the United States.Obstet. Gynecol. 2022; 139: 440-442https://doi.org/10.1097/AOG.0000000000004676
- Howlader N. Noone A.M. Krapcho M. Miller D. Brest A. Yu M. Ruhl J. Tatalovich Z. Mariotto A. Lewis D.R. Chen H.S. Feuer E.J. Cronin K.A. SEER Cancer Statistics Review, 1975–2018. National Cancer Institute, Bethesda, MDApril 2021based on November 2020 SEER data submission, posted to the SEER web site)
- Follow-up after primary therapy for endometrial cancer: a systematic review.Gynecol. Oncol. Jun 2006; 101 (Epub 2006 Mar 23. PMID: 16556457): 520-529https://doi.org/10.1016/j.ygyno.2006.02.011
- Recurrence patterns and surveillance for patients with early stage endometrial cancer.Gynecol. Oncol. 2011; 123: 205-207https://doi.org/10.1016/j.ygyno.2011.07.014
- Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial.Lancet. 2000; 355: 1404-1411https://doi.org/10.1016/S0140-6736(00)02139-5
- Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment.Int. J. Gynecol. Cancer. 2020; 30: 193-200https://doi.org/10.1136/ijgc-2019-000822
- Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy.Gynecol. Oncol. Jul 2019; 154 (Epub 2019 Apr 24. PMID: 31029507): 38-44https://doi.org/10.1016/j.ygyno.2019.04.676
- Endometrial cancer: who lives, who dies, can we improve their story?.Oncologist. 2021; 26: 1044-1051https://doi.org/10.1002/onco.13934
- Chemotherapy in endometrial cancer.Clin. Adv. Hematol. Oncol. 2006; 4: 459-468
- Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high risk early stage endometrial cancer.J. Clin. Oncol. 2019; 37: 1810-1818
- Adjuvant chemoradiotherapy versus radiotherapy alone in women with high risk endometrial cancer (PORTEC-3): patterns of recurrence and post hoc survival analysis of a randomized phase 3 trial.Lancet Oncol. 2019; 20: 1273-1285
- Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.N. Engl. J. Med. 2019; 380: 2317-2326
- Uterine Neoplasms Version 1.2021. Plymouth Meeting.National Comprehensive Cancer Center, PA2022 (Available at)2022)
- Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.Gynecol. Oncol. 2019; 152: 522-527https://doi.org/10.1016/j.ygyno.2018.12.010
- Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.Gynecol. Oncol. 2007; 107: S241-S247https://doi.org/10.1016/j.ygyno.2007.07.025
- Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.Gynecol. Oncol. Oct 1995; 59 (PMID: 7557610): 20-24https://doi.org/10.1006/gyno.1995.1262
- Five Things Physicians and Patients Should Question.Choosing Wisely, Philadelphia, PA2021 (Available from:)Accessed 2022 June 22)
- Effectiveness of intensive versus minimalist follow-up regimen on survival in patients with endometrial cancer (TOTEM study): a randomized, pragmatic, parallel group, multicenter trial.J. Clin. Oncol. 2022; https://doi.org/10.1200/JCO.22.00471
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur. J. Cancer. 2009; 45: 228-247
- The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients.Int. J. Gynecol. Cancer. 2004; 14: 931-937https://doi.org/10.1111/j.1048-891X.2004.014532.x
- The nature of early-stage endometrial cancer recurrence—a national cohort study.Eur. J. Cancer. 2016; 69: 51-60https://doi.org/10.1016/j.ejca.2016.09.033
- Is there any value in the long term follow up of women treated for endometrial cancer?.BJOG. 1996; 103: 710-713https://doi.org/10.1111/j.1471-0528.1996.tb09843.x
- An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.Anticancer Res. 2000; 20 (May–Jun. (PMID: 10928137)): 1977-1984
- Costs and benefits of routine follow-up after curative treatment for endometrial cancer.CMAJ. 1997; 157: 879-886
- An evaluation of routine follow-up of patients treated for endometrial carcinoma.Gynecol. Oncol. 1994; 55: 229-233
- Stratification of risk groups according to survival after recurrence in endometrial cancer patients.Medicine. 2017; 96e6920https://doi.org/10.1097/MD.0000000000006920
- Gynecologic cancer survivor preferences for long-term surveillance.BMC Cancer. 2018; 18 (Published 2018 Apr 3): 375